Search Results

1 - 10 of 11 items :

  • "innovation" x
  • Internal Medicine x
  • Endocrinology, Diabetology x
Clear All
Euglycemic Ketoacidosis Diagnosis and Treatment Protocol in Type 1 Diabetes Patient

Abstract

Introduction. The introduction of sodium glucose cotransporter 2 inhibitors in the management of diabetes was an innovation in the treatment of this disease, considering the protective cardiovascular effect not only the ability of decreasing the plasma glucose. In Europe, this class of medication is approved for the treatment of type 2 diabetes and some of them (dapagliflozin and sotagliflozin) are also approved for use in certain patients with type 1 diabetes mellitus. These patients must have inadequate control of their blood glucose levels despite optimal insulin therapy. One of the adverse effects is diabetic ketoacidosis.

Case report. This case report presents a diabetic patient whose treatment was changed from insulin therapy to oral therapy. Within 10 days after the initiation of the new treatment her condition gradually worsened and she arrived at the emergency room with nausea, vomiting and altered general condition. She was admitted for euglycemic ketoacidosis and treated according to the protocol.

Conclusions. This case reveals the importance of continuing the insulin therapy when adding a sodium glucose cotransporter 2 inhibitor in type 1 diabetes patients.

Open access
The Analysis of Prevalence and Incidence of Diabetes Mellitus in Romania

References 1. World Health Organization . Noncommunicable Diseases Country Profiles 2011. WHO Global Report. Geneva, Switzerland: WHO, 2011. Accessed on January 05, 2013 at: http://www.who.int/nmh/publications/ncd_profiles2011/en/ 2. Kaplan W, Laing R . Priority medicines for Europe and the world - a public health approach to innovation. Geneva: World Health Organization ; 2004. Accessed on January 05, 2013 at: http://whqlibdoc.who.int/hq/2004/WHO_EDM_PAR_2004.7.pdf 3. International Diabetes

Open access
Updates in Parenteral Nutrition

References 1. Agency for Clinical Innovation. Parenteral nutrition pocketbook: for adults. Chatswood, Australia: Agency for Clinical Innovation, 2011. 2. Kumpf VJ, Mirtallo JM, Peterson C. Parenteral Nutrition Formulation: Preparation and Ordering. In: The A.S.P.E.N. Nutrition Support Practice Manual, 2nd ed; Merritt R (eds); Silver Spring, pp 97-108, 2005. 3. American Society for Parenteral and Enteral Nutrition. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN - J Parenter Enteral Nutr 26 (1 Suppl

Open access
Moderate-Vigorous Physical Activity and Clinical Parameters in Adults with Type 2 Diabetes Mellitus: A Report from the Walking with Diabetes Study

around the world. McKinsey’s Center for Healthcare Research and Innovation (CHRI) 2016. 5. Colberg SR, Sigal RJ, Yardley JE et al . Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care 39(11): 2065-2079, 2016. 6. Rader DJ . Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 120(3): S12-S18, 2007. 7. Long AN, Dagogo-Jack S . Comorbidities of diabetes and hypertension: mechanisms and

Open access
Dr. Google, The Specialist in Diabetes and Metabolic Diseases

devices are transforming healthcare. Issues in Technology Innovations, 2012. [Online]. http://www.insidepolitics.org/brookingsreports/ mobile_health_52212.pdf. 11. Katz JE, Rice RE. Public views of mobile medical devices and services: a US national survey of consumer sentiments towards RFID healthcare technology. Int J Med Inform 78: 104-14, 2009. 12. *** Mobile Medical applications. FDA, Center for Devices and Radiological Health, 2013. [Online]. http://www.fda.gov/MedicalDmevices/ProductsandMedica lProcedures/ConnectedHealth/MobileMedicalApplications /default

Open access
The Impact of Psychological Interventions on the Quality of Life of Diabetes Mellitus Patient

& Company Press, pp. 6-147, 2008. 31. Fisher EB, Walker EA, Bostrom A et al. Behavioral science research in the prevention of diabetes: status and opportunities. Diabetes Care 25: 599-606, 2002. 32. Fisher P, Wells A. Innovation in treating depression: metacognition, acceptance, behavioral activation and mindfulness. John Wiley & Sons Press, pp.54-170, 2013. 33. Wing RR, Goldstein MG, Acton KJ et al. Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity

Open access
Agglomeration effect of medical education: Based on the web of science database

into eight types: knowledge spillover effect, innovation effect, scale effect, time effect, information sharing effect, collective learning effect, incentive effect and regional effect. From the various expositions on the meaning of talent agglomeration, it can be seen that while the concept is stated differently by different researchers, all nevertheless highlight the essence of talent agglomeration, namely, talent agglomeration is a special phenomenon in the flow of talents and the action or phenomenon of clustering of individual talents in geographical space

Open access
The progress of traditional Chinese medicine in the treatment of aplastic anemia

prospective, randomized, and multicenter studies are the main research directions in the future. Innovation is needed in the scientific research in TCM. The TCM research that meets the clinical needs, aims to improve the level of prevention and treatment of major diseases in China, will get further developed. Source of Foundation The present study was supported by the Special Research Funds for Traditional Chinese Medicine Industry from State Administration of Traditional Chinese Medicine (201407001) and National Natural Science Foundation Project (grant No. 81774092

Open access
Identifying the optimal blood pressure target for ideal health

of hypertension in China and in other populations with similar characteristics. Sources of Financial Support Including from the Projects of National Natural Science Foundation of China (grants No. 81473052, 81441091, and 81402735); the Major State Basic Research Development Program of China (973 program) (2012 CB517703); Clinical Center (grant No. zx09401013); National Science and Technology Major Projects Specialized for “Major New Drugs Innovation and Development” during the 12th Five-Year Plan Period: China Stroke Primary Prevention Trial (grant No. zx

Open access